Pathogen Dimorphism
The causative agent of coccidioidomycosis is the fungus Coccidioides immitis. Its primary biological feature is dimorphism. Depending on environmental conditions, it exists in two fundamentally different developmental phases:
- Mycelial (Saprophytic) Phase
- Develops in the external environment (soil) or during laboratory culture at 25 °C.
- Structure: Forms thin, colorless, septate hyphae.
- Reproduction: Occurs via the formation of characteristic barrel-shaped arthrospores.
- Significance: The mycelial phase with arthrospores is infectious and poses a hazard to humans.
- Tissue (Parasitic) Phase
- Develops exclusively inside the host organism (found in sputum, organs, and tissues).
- Structure: Forms large spherules (12 to 200 µm in diameter).
- Contents: Maturing spherules contain numerous small endospores (2–5 µm in size).
- Life cycle: Upon maturation, endospores rupture from the spherules, grow, and transform back into new spherules, completing the cycle within the host.
- Significance: The tissue form is not contagious to others.
Epidemiology and Pathogenesis
Coccidioidomycosis has a distinct geographic distribution: the infection is endemic to the arid regions of the southwestern United States and Latin America. The reservoir and primary source of the pathogen are soils containing arthrospores.
Infection occurs predominantly via the airborne dust route (aerosol mechanism). Humans inhale arthrospores along with dust; contact transmission occurs less frequently. The incubation period ranges from one to six weeks.
Stages of infection development in the body:
- Fungal arthrospores enter the respiratory tract.
- Transformation of the pathogen into the parasitic tissue form (spherule).
- Massive release of endospores from mature spherules, disseminating throughout the body.
- Formation of secondary foci of infection in various systems and organs.
Clinical Forms and Immunity
Coccidioidomycosis can manifest in several clinical variants:
- Primary pulmonary infection. Often presents with influenza-like symptoms.
- Allergic manifestations. May include cutaneous reactions such as erythema nodosum or erythema multiforme.
- Disseminated forms. The most severe clinical course, accompanied by deep involvement of the skin, bones, joints, and internal organs.
In response to C. immitis invasion, cell-mediated immunity develops. The immune reaction proceeds via delayed-type hypersensitivity (DTH).
Microbiological Diagnostics
Important: Because C. immitis is a high-consequence (highly virulent) pathogen, all procedures involving it must be performed strictly in specialized laboratories equipped with laminar flow hoods. Test specimens include sputum, pus, blood, urine, or cerebrospinal fluid.
Comprehensive diagnostics include the following methods:
- Microscopy
Aiming to detect characteristic spherules and endospores in specimens. Visualization methods include hematoxylin and eosin staining, Van Gieson stain, Wright stain, Gomori methenamine silver or Gram-Weigert stains, and the PAS (Periodic acid–Schiff) reaction.
- Mycological (Culture) Method
Inoculation is performed on Sabouraud dextrose agar and standard media, incubated at 25 °C. Grayish, fluffy colonies grow in approximately one week, revealing the mycelial phase of the pathogen (hyphae, chlamydospores, arthrospores).
- Serological Testing
Detection of specific antibodies in blood serum using precipitation tests, indirect hemagglutination assays (IHA), and complement fixation tests (CFT).
- Immunodiagnosis (Skin Tests)
Cutaneous hypersensitivity testing using allergens from different developmental phases: coccidioidin (from the mycelial phase) or spherulin (from the tissue phase).
- Animal Inoculation (In Vivo)
Experimental infection of laboratory animals (white mice or hamsters). A mycelial suspension is injected intratesticularly to observe the subsequent transformation of the fungus into the tissue phase (formation of typical spherules).
First-line agents for targeted treatment include fluconazole, itraconazole, or amphotericin B.